{"id":"chimerivax-je","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine uses a recombinant approach where the structural genes of Japanese encephalitis virus are inserted into an attenuated yellow fever vaccine (17D) backbone. This chimeric construct allows the vaccine to stimulate both humoral and cellular immune responses against Japanese encephalitis virus while maintaining the safety profile of the yellow fever vaccine platform. The resulting vaccine provides protection against Japanese encephalitis infection through neutralizing antibody production and T-cell mediated immunity.","oneSentence":"ChimeriVax-JE is a live attenuated chimeric vaccine that combines the yellow fever vaccine backbone with Japanese encephalitis virus envelope genes to induce protective immunity against Japanese encephalitis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:39.082Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Japanese encephalitis prevention in endemic regions"}]},"trialDetails":[{"nctId":"NCT00735644","phase":"PHASE3","title":"Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-08","conditions":"Japanese Encephalitis, Hepatitis A","enrollment":1200},{"nctId":"NCT00621764","phase":"PHASE2","title":"Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-03","conditions":"Japanese Encephalitis, Hepatitis A","enrollment":300},{"nctId":"NCT00314132","phase":"PHASE3","title":"Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-10","conditions":"Encephalitis, Japanese Encephalitis","enrollment":2004},{"nctId":"NCT00314145","phase":"PHASE3","title":"A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-11","conditions":"Japanese Encephalitis","enrollment":820},{"nctId":"NCT00981630","phase":"PHASE2","title":"Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-11","conditions":"Japanese Encephalitis","enrollment":128},{"nctId":"NCT00982137","phase":"PHASE2","title":"Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-07","conditions":"Japanese Encephalitis, Yellow Fever","enrollment":108},{"nctId":"NCT00441259","phase":"PHASE2","title":"Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-01","conditions":"Japanese Encephalitis","enrollment":96},{"nctId":"NCT00319592","phase":"PHASE2","title":"A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-05","conditions":"Japanese Encephalitis","enrollment":60},{"nctId":"NCT00981175","phase":"PHASE2","title":"A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-04","conditions":"Encephalitis, Japanese Encephalitis","enrollment":202}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ChimeriVax™-JE","genericName":"ChimeriVax™-JE","companyName":"Sanofi","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"ChimeriVax-JE is a live attenuated chimeric vaccine that combines the yellow fever vaccine backbone with Japanese encephalitis virus envelope genes to induce protective immunity against Japanese encephalitis. Used for Japanese encephalitis prevention in endemic regions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}